Human prion diseases are characterized by the conversion of the normal prion protein (PrP C ) into a pathogenic isomer (PrP Sc ). Distinct PrP Sc conformers are associated with different subtypes of prion diseases. PrP C binds copper and has antioxidation activity. Changes in metal-ion occupancy can lead to signi®cant decline of the antioxidation activity and changes in conformation of the protein. We studied the trace element status of brains from patients with sporadic Creutzfeldt±Jakob disease (sCJD). We found a decrease of up to 50% of copper and an increase in manganese of approximately 10-fold in the brain tissues from sCJD subjects. We have also studied the metal occupancy of PrP in sCJD patients. We observed striking elevation of manganese and, to a lesser extent, of zinc accompanied by signi®cant reduction of copper bound to puri®ed PrP in all sCJD variants, determined by the PrP genotype and PrP Sc type, combined.
The central event in the pathogenesis of prion diseases, which include Creutzfeldt±Jakob disease (CJD) in humans and scrapie in animals, is believed to be the posttranslational conversion of the normal cellular prion protein (PrP C ) into an abnormal isoform called scrapie PrP (PrP Sc ) that is partially resistant to proteases and is associated with transmissible disease (Prusiner 1998) . Recent studies have showed that PrP C not only binds copper (Cu) within the octarepeat region located in the unstructured N-terminus , but under certain speci®c circumstances may bind along the C-terminal structured domain of protein fragments (Cereghetti et al. 2001) . Furthermore, recombinant PrP C can also bind other metal ions such as manganese (Mn) at both the octarepeats and the C-terminal sites (Collinge 2001) . However, when Mn replaces Cu, PrP reportedly changes conformation and loses function . Indeed, accumulating evidence suggests that metallochemical alterations may play a role in the pathogenesis of prion diseases and other neurodegenerative diseases (Bush 2000) .
Increasing evidence indicates that the phenotypic diversity of prion diseases is related to the multiple conformations that PrP Sc may adopt (Monari et al. 1994; Parchi et al. 2000) . Two major, but not exclusive, determinants of the disease phenotype in sporadic CJD (sCJD) are thought to be the genotype at codon 129, the site of a common methionine (M)/valine (V) polymorphism (Goldfarb et al. 1992) , and the PrP Sc type as determined by the size of the proteaseresistant PrP Sc , which in turn, is an indication of the PrP Sc conformation (Monari et al. 1994; Parchi et al. 1999 Parchi et al. , 2000 . Two main types and several minor types of PrP Sc have been observed in CJD (Parchi et al. 1999 (Parchi et al. , 2000 . PrP
Sc type-1 and type-2 results from the cleavage of PrP Sc by proteinase K (PK) at residues 82 and 97, respectively, while secondary cleavages around the two main cleavage sites generate the minor PrP Sc types (Parchi et al. 2000) . It has been proposed that in sCJD, the genotype at codon 129 affects the conformation of PrP Sc and thus the site of protease cleavage (Parchi et al. 2000) . In turn, PrP
Sc species with different conformations have been associated with distinct disease phenotypes (Monari et al. 1994; Telling et al. 1996; Parchi et al. 2000) . Indirect evidence suggests that the level of metal-ion occupancy in PrP might also affect the conformation of PrP Sc associated with human prion diseases (Wadsworth et al. 1999) .
It has been demonstrated that both recombinant and brainderived PrP have superoxide dismutase (SOD)-like activity when Cu is bound to the octarepeat region resulting in conformational changes to the protein Wong et al. 2000b) . When Cu is replaced with Mn in recombinant PrP, it loses the SOD-like activity . At the same time, there is increasing evidence linking oxidative stress to several neurodegenerative diseases (Bush 2000) , including animal prion disease (Guentchev et al. 2000) . All these motivate us to investigate (i) whether, like in Alzheimer's disease (Deibel et al. 1996) , metal binding is altered in sCJD, the most common human prion disease, (ii) whether these alterations correlate with disease phenotype such as PrP Sc type and PrP genotype at codon 129, and (iii) whether metal imbalances also correlate with PrP loses antioxidant function. These studies were carried out in brain tissues and af®nity puri®ed PrP preparations (i.e. PrP C , PrP Sc and possibly other abnormal PrP species) obtained from four major variants of sCJD identi®ed according to the genotype at codon 129 of the PrP gene and the PrP Sc type as established by Parchi et al. (1999) . We report that Cu binding to PrP puri®ed from sCJD was signi®cantly decreased while the binding of Mn and Zn was markedly increased. The diminution of bound Cu was especially severe in PrP preparations containing PrP Sc type-1, while bound Mn showed a more pronounced increase in PrP preparations from sCJD subjects homozygous for methionine (MM) at codon 129. SOD-like activity was reduced by approximately 85% in each of the sCJD variants examined.
Materials and methods
Unless described, all chemicals and enzymes were purchased from Sigma (St Louis, MO, USA) and Roche Diagnostic (Indianapolis, IN, USA), respectively.
Tissues
Brain tissues were obtained with informed consent at autopsy from the frontal cortex of nine subjects with clinically and pathologically proven sCJD in the USA, and they were deposited at the National Prion Disease Pathology Surveillance Center in Cleveland, OH, USA. The genotype for codon 129 of the PrP gene (PRNP), which encodes a methionine (M) or valine (V) polymorphism, in each sCJD sample was determined by sequencing and restriction digests of the ampli®ed PRNP fragment as described (Goldfarb et al. 1992) . The sCJD cases were classi®ed according to the criteria proposed by Parchi et al. (1999) : (i) Four cases carried PrP Sc type-1 which include the MM type-1 variant (n 3) and the clinically rare VV type-1 variant (n 1) (Parchi et al. 1999) ; (ii) ®ve cases carried PrP Sc type-2 including the VV type-2 variant (n 3) and the infrequent MM type-2 variant (n 2) (Parchi et al. 1999) ; in addition, (iii) three cases in which the presence of prion diseases had been ruled out were used as controls. Brain homogenate was prepared and total protein concentrations measured as described (Parchi et al. 2000; Wong et al. 2001) .
Antibodies
The monoclonal anti-PrP 8H4 recognized an epitope between residue 175±185 along human PrP (Zanusso et al. 1998) , and it has been demonstrated to react equally well with both normal and abnormal PrPs (Zanusso et al. 1998; Manson et al. 1999) . Puri®ed goat polyclonal antibody to actin was purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA), while sheep polyclonal antibodies against Cu/Zn-SOD and Mn-SOD were purchased from Calbiochem (San Diego, CA, USA).
PrP puri®cation and immunodetection
The puri®cation of PrP from brain homogenates was performed as described . Brie¯y, anti-PrP 8H4 antibody was coupled to cyanogen bromide activated Sepharose beads (Amersham, Piscataway, NJ, USA) before mixing with the brain extracts overnight at 48C. After extensive washing, the protein was eluted from the beads with glycine (pH 4) and neutralized with Tris±HCl (pH 8) followed by assessing the eluted protein by immunoblotting and silver staining (Pierce, Rockford, IL, USA). The puri®ed protein was quanti®ed by spectrophotometry to ensure identical amounts of protein were taken and boiled in loading buffer before separation by electrophoresis (Novex, Los Angeles, CA, USA), transferred to nitrocellulose, probed with primary and horseradish peroxidase (HRP)-conjugated secondary antibodies, respectively, and analysed for immunoreactivity using the POD chemiluminescence kit (Roche Diagnostic, Indianapolis, IN, USA) (Wong et al. 2001) .
ICP-MS analysis
Trace element contents of both brain homogenate and immunoprecipitated protein samples were determined using inductively coupled plasma mass spectrometry (ICP-MS) (Beauchemin and Kisilevsky 1998) . PrP was af®nity puri®ed from brain homogenate as described ) using 8H4-coupled Sepharose beads (Amersham). The concentrations of total protein in the brain homogenate and of immuno-puri®ed PrP were determined by spectrophotometry . Before analysis, all lab-ware was acid-leached overnight under pressure to minimize residual metal contaminants (Beauchemin and Kisilevsky 1998) . Samples were hydrolysed overnight in nitric acid (1 mL SpA grade per 100 mL sample) at room temperature (248C). They were then sealed and heated under pressure and temperature control to 120 psi and at least 1408C for 10 min. The resulting cleared hydrolysed samples were diluted to 4% nitric acid before analysing for Cu, Mn and Zn contents. Quantitative calibrations were made using standards prepared from certi®ed single elements (1000 ppm standard solutions). The concentrations used were 0, 2, 4, 6, 8, 10, 20, 40, 60, 80 and 100 ppb and each solution contained 100 ppb internal standard to monitor the analysis. Each sample was analysed at least three times, washed with 2% nitric acid for 110 s between solutions. A 10 ppb standard check solution was analysed after each set of samples to monitor the analysis. The dilution factors were recorded and accounted for in the calculation of the results, quoted in gram wet weight or mg/mg protein. Background measurements without homogenate or with 8H4-coupled Sepharose beads not mixed with brain homogenate were determined and subtracted from appropriate readings.
Superoxide dismutase assay SOD activity of af®nity-puri®ed PrP was determined as described employing superoxide production from xanthine oxidase and detection of a coloured formazan product formed from nitro-blue tetrazolium (NBT) at 560 nm. The SOD activity was expressed as percentage inhibition of formazan produced where 100% formazan product formation is the amount of NBT reduced by xanthine oxidase-formed radicals in control reactions without brain extracts or immuno-puri®ed PrP. For Mn SOD activity measurement, PrP-depleted brain extracts were incubated at room temperature in 4 mm KCN for 20 min before assaying. Cu/Zn SOD activity was calculated by subtracting Mn SOD activity from total SOD activity in the PrP-depleted brain homogenates. All assays were performed in triplicate.
Reactive carbonyl assay of oxidized proteins Protein oxidation in brain homogenates was measured by assaying the amount of carbonyl groups on proteins using the OxyBlote Protein Oxidation Detection Kit (Intergen, Boston, MA, USA). The procedure was performed as described (Wong et al. 2001) , according to manufacturer's recommendation, by derivatizing brain homogenates with 2,4-dinitrophenyl-hydrazine (DNPH) before loading onto a reducing 4±20% linear gradient sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS±PAGE) (Novex). The proteins were then electrotransferred, probed with a rabbit antiserum against the derivatized carbonyl groups and visualized using the PODe chemiluminescence kit (Roche). No immunoreactivity was detected in the non-DNPH derivatized brain lysates (data not shown). Each sample was analysed at least three times.
Lipid peroxidation assay
Lipid peroxidation, via the levels of malondialdehyde (MDA) and 4-hydroxyalkenals (4-HNE), in brain homogenate was measured using the N-methyl-2-phenylindole-based LPO-586e lipid peroxidation kit (Oxis International, Portland, OR, USA) as described (Wong et al. 2001) . Standard curves of both MDA and 4-HNE were established. To minimize non-speci®c oxidation during sample preparation, 5 mm butylated hydroxytoulene (BHT) (dissolved in acetonitrile) was added to the extraction buffer. The assay was performed in triplicates according to manufacturer's recommendation in which identical amount of total brain lysates were mixed with 0.5 m BHT and 0.1 mm N-methyl-2-phenylindole. For MDA measurement, 150 mL of reagent grade HCl was added, whereas for 4-HNE measurement 150 mL of 15.4 m methanesulfonic acid was added. The sample was mixed, incubated for 1 h at 458C, supernatant extracted after brief centrifugation before reading at 586 nm.
Statistical analysis
The data obtained in the metals analysis was analysed by two-tailed distribution Student's t-test. The signi®cance of the differences for the superoxide dismutase activity and lipid peroxidation analysis was assessed using paired sample one-tailed distribution Student's t-test.
Results

PrP
Sc species The main distinction between PrP C and PrP Sc is not the primary sequence but has been postulated to be their protein conformation (Prusiner 1998) . In prion-infected brains, PrP Sc together with PrP C and other abnormal forms of PrP (include the suggested intermediary between PrP C conversion to PrP Sc , termed PrP*) are present, in contrast to the preponderant of PrP C in non-diseased situation (Caughey 2000; Parchi et al. 2000) . The conformation adopted by PrP Sc allegedly makes the protein partially resistant to protease digestion, which resulted in generating a truncated PrP fragment designated as PrP27-30 (Prusiner 1998) . This proteolytic process is the current mean of discriminating between PrP C and PrP Sc , but the cleavage removed the main metal-binding octarepeat region (Parchi et al. 2000) . Paradoxically, the protease-sensitive PrP* has also been implicated in certain prion transmissions (Lasmezas et al. 1997; Caughey 2000) . As a result of this, we decided to examine total PrP (including PrP C , PrP
Sc and other abnormal forms of PrP) in the brain homogenates obtained from four groups of sCJD cases which were homozygous for methionine (MM) or valine (VV) at codon 129 of the PrP gene and carried PrP Sc type-1 or type-2 (Parchi et al. 1997 (Parchi et al. , 1999 . Cases heterozygous at codon 129 were not analysed because following PK treatment the PrP Sc species present in sCJD cases that are MV heterozygous at position 129 generate fragments similar in size to those generated in VV homozygous cases suggesting that PrP Sc in MV and VV cases have comparable conformations (Parchi et al. 2000) . PrP preparations from the control and four sCJD groups untreated with PK showed similar reactivity for the monoclonal antibody (mAb) to PrP 8H4 (Fig. 1a , left panel). Following treatment with PK, all the PrP Sc species in sCJD samples migrated faster on the gel but, as expected, PrP Sc type-2 migrated faster than type-1 (Monari et al. 1994; Parchi et al. 2000) : the unglycosylated form of PrP Sc type-1 migrated at ,21 kDa while that of type-2 migrated at ,19 kDa (Fig. 1a, right panel) . PrP preparation from control was totally digested by proteinase K, con®rming they contain only the PrP C isoform.
Direct measurement of metal binding by PrP
Analysis of short peptides encompassing the octarepeat region suggests Cu bind with a surprising low dissociation constant (mm range) (Whittal et al. 2000) . However, other studies indicate that both the octarepeat region at the N-terminal and the binding sites along the C-terminal in human PrP can binds Cu with a signi®cantly higher af®nity (K d ) of 10 214 M (Collinge 2001 ). These observations suggest that studies using synthetic peptides do not truly re¯ect the interaction between full-length PrP and metal ions. Furthermore, no detectable loss of the bound metal was observed after af®nity purifying PrP . Besides Cu, PrP can also binds Mn and Zn, but not Mg, Fe or Ca in vitro Collinge 2001) .
We therefore decided to measure the amount of Cu, Mn and Zn bound to af®nity puri®ed PrP. The preparation was assessed by immunoblotting using anti-PrP 8H4 (Fig. 1b , left panel) and silver staining (Fig. 1b, right panel) . The metal content of PrP from both control and sCJD brains was assessed using inductively coupled plasma mass CJD samples (right panel) after proteinase K treatment (50 mg/mL for 1 h at 378C) (Parchi et al. 1999 ) detected with anti-PrP 8H4 which has been shown to react equally well with both normal and abnormal PrP (Zanusso et al. 1998; Manson et al. 1999) . Note the different gel mobility of the protease-resistant PrP Sc fragment in the type-1 and 2 preparations (Parchi et al. 2000) . (b) Af®nity-puri®ed PrP using 8H4-coupled Sepharose beads were assessed by (left panel) immunoblotting using anti-PrP 8H4 (Zanusso et al. 1998; Li et al. 2000) and (right panel) silver staining. 
Metal concentrations in brain homogenates
We next determine whether the altered metal binding by puri®ed PrP in sCJD variants was associated with perturbations in the metals concentration in the frontal cortex. ICP-MS analysis showed that Cu cations were signi®cantly decreased by up to 50% while Mn cations were markedly increased by up to 10-fold in the brain homogenates from all sCJD cases combined as compared with controls (Table 2) . When all the sCJD cases were grouped according to the 129 genotype regardless of the PrP Sc type, the MM cases showed a signi®cantly more severe decrease in Cu level and a more prominent increase in Mn level than the VV cases (Table 2) . Both groups were also signi®cantly different from controls (Table 2) . In contrast, when the sCJD cases were grouped according to the PrP Sc type, no signi®cant difference in Cu and Mn levels was observed between the PrP Sc type-1 and type-2 cases, although again both groups signi®cantly differed from controls in the level of these metals (Table 2) . No signi®cant difference in the Zn levels was observed between all sCJD cases combined and controls. The Zn levels were signi®cantly different between the sCJD cases type-1 and 2 but not between the MM and VV cases.
Anti-oxidation activity of PrP
Since the metal perturbations that we have observed in sCJD may impair the antioxidation function associated with PrP C , we therefore measured the SODlike activity of af®nity puri®ed PrP ) from the sCJD preparations grouped according either to the PrP genotype or PrP Sc type using the NBT-based SOD assay . The SOD activity was markedly reduced in all PrP species puri®ed from sCJD and represented only approximately 15% of the control values (Fig. 1c) . The observed SOD-like activity was not due to the presence of either Cu/Zn-SOD or Mn-SOD as they were not immunodetected in the puri®ed PrP preparations (data not shown). Signi®cant difference was observed between the MM and VV cases, and also between preparations containing PrP Sc type-1 and those containing PrP Sc type-2. The SOD activity of PrP puri®ed from sCJD cases associated with VV homozygousity and PrP Sc type-2 are the most severely reduced.
Cu/Zn-SOD and Mn-SOD activity
We also assessed the activities of Cu/Zn-SOD and Mn-SOD, two other related antioxidation enzymes that are not associated with PrP, in the brain homogenates immunodepleted of PrP. The ef®ciency of the immunodepletion process has been demonstrated previously (Wong et al. 2000a ). In the PrP-immunodepleted brain homogenates, there was no signi®cant difference in the levels of Cu/Zn-SOD and Mn-SOD activities among the sCJD cases grouped according to the PrP Sc type (Fig. 2a) . When the sCJD cases were grouped by their codon 129 genotype, only PrP-depleted brain homogenates from the MM sCJD cases showed a signi®cant reduction of the Cu/Zn-SOD activity as compared with the VV sCJD cases (Fig. 2a) . In contrast, the Cu/Zn-SOD and Mn-SOD activity from sCJD samples were signi®cantly difference between the respective sCJD variants, as determined by the prion protein genotype (white bars) of MM (n 5) and VV (n 4), and also by the scrapie prion protein type-1 (n 4) and 2 (n 5) (grey bars), with the control value (black bar, n 3). ³ There are also signi®cant different between the two codon 129 genotypes of sCJD variants (Student's t-test, p , 0.001). All values represent the mean^SEM (the positive and negative error bars are of the same value) of three assays for each sample. (b) Immunodetection was performed using 30 mg and 80 mg of brain homogenates for Cu/Zn-SOD and Mn-SOD, respectively. All samples were separated and immunoblotted on the same gel. Actin was immunoblotted to ensure similar gel loading of the starting preparation.
different from those of controls. Cu/Zn-SOD activity was signi®cantly reduced in the sCJD groups, while Mn-SOD activity was more than twofold higher in the sCJD groups as compared with control. These variations in activities were not due to increase expression of Cu/Zn-SOD or Mn-SOD, which was present in similar amounts in both sCJD and control brains (Fig. 2b) .
Oxidative stress in the brains Since oxidative stress has been shown to be a pivotal event in the brains of scrapie-infected animals (Guentchev et al. 2000) , we looked for similar evidence in the frontal cortex of sCJD subjects using two established markers for cellular oxidative damage: protein oxidation (Berlett and Stadtman 1997; Halliwell and Gutteridge 1999; Butter®eld and Kanski 2001) and lipid peroxidation (Halliwell and Gutteridge 1999) . The immunoreactivity of carbonyl groups was markedly increased in all sCJD samples compared with the controls (Fig. 3) . The levels of two products of lipid peroxidation, malonaldehyde (MDA) (Fig. 4a ) and 4-hydroxyalkenals (4-HNE) (Fig. 4b ) assayed in each of the sCJD groups were double those of the controls. These results indicate that sCJD brains undergo oxidative stress, which is likely to be related to the marked decline of the antioxidation activity by the PrP (Fig. 1c) .
Discussion
Recent advances add new complexity to the pathogenesis of prion diseases. As originally proposed, the prion hypothesis postulates that a change in conformation leads to the conversion of PrP C to PrP Sc , which then causes the disease (Prusiner 1998) . Now it appears that metal-ions such as Cu and Mn, may contribute to the pathogenesis of prion diseases. It is well established that PrP C binds Cu Cereghetti et al. 2001) , but recent data suggest that PrP C binding of Cu is needed to induce conformational changes Wong et al. 2000b ) that enable PrP C to function as an antioxidant . On the other hand, the replacement of Cu by other metals such as Mn, not only causes the loss of this antioxidant activity but also increases PrP b-sheet content and resistance to proteases suggesting that these aberrations in metal binding change the conformation of PrP . According to Wadsworth et al. (1999) the conformation of some of the PrP Sc species associated with speci®c CJD phenotypes could be affected by the level of metal binding in vitro. Therefore, these results collectively argue or are based on an indirect approach (Wadsworth et al. 1999) . In this report, we directly measured and compared with controls the quantities of Cu, Mn and Zn cations as well as the SOD-like activities that are present in brain tissues or are directly associated with af®nity puri®ed PrP (PrP C , PrP Sc and possibly other abnormal PrP species) obtained from human subjects affected by the major phenotypic variants of sCJD. We found a striking decrease of bound Cu and quantities of Mn cations exceeding those of Cu in the puri®ed PrP preparations from sCJD subjects as compared with controls, while Mn cations were undetectable in PrP C preparations from controls. Similarly, Zn cations were detectable only on PrP preparations isolated from sCJD subjects. These changes were also accompanied by striking alterations in the brain metals concentrations; a signi®cant decrease of Cu cations and a dramatic increase of Mn cations in brain tissues from sCJD subjects. These metal binding aberrations were associated with an , 85% diminution of the SOD-like activity of PrP present in sCJD. The present data suggest that in sCJD, Mn and perhaps Zn replace Cu in binding to the total PrP population (PrP C , PrP Sc and related abnormal PrP species), and that this replacement leads to the loss of the SOD-like activity associated with PrP C found in non-CJD. They also support the suggestion that metal binding aberrations may play a role in the pathogenesis of prion diseases by causing the loss of the antioxidation function associated with PrP C . The sizable increase of markers associated with oxidative damage, such as protein oxidation and lipid peroxidation end products, also argue for a failure of antioxidation activities in sCJD. Currently, oxidative stress is thought to be a pivotal event in several neurodegenerative diseases although it is likely that the mechanisms leading to it are different in the various diseases (Bush 2000; Butter®eld and Kanski 2001) . Indeed, to our knowledge the elevation in Mn that we showed to be so prominent in brain tissue and PrP preparations from subjects with sCJD has not been reported in other neurodegenerative diseases. Alterations in brain Cu and Zn (Deibel et al. 1996) but not Mn (Markesbery et al. 1984) have been observed in Alzheimer's disease. Moreover, the level of Mn does not change signi®cantly during aging (Markesbery et al. 1984) .
The alterations in metal binding we observed were not uniformly distributed among the different phenotypic variants of sCJD as determined by the genotype at codon 129 of the PrP gene and the PrP Sc type. In brain tissue, the changes in Cu and Mn cations were more prominent in the variants associated with MM homozygosity than with VV homozygous variants while no de®nite difference was detected according to the PrP Sc type. In contrast, Cu was decreased signi®cantly more in puri®ed preparations containing PrP Sc type-1 than in those with PrP Sc type-2. However, Mn increase was more prominent in MM homozygous cases. Combined, our data show that MM homozygosity at codon 129 and the presence of type-1 PrP Sc are the two conditions associated with the most pronounced changes in Cu and Mn. Accordingly, the sCJD variant MM type-1, which corresponds to the classical and by far the most common CJD subtype (Parchi et al. 1999) , has the most prominent Cu and Mn variations. Zn cations appear to distribute differently, since in brain tissue they are signi®cantly decreased in cases carrying PrP Sc type-1 and increased in the PrP Sc type-2 cases, while in PrP preparations they are increased in all preparations but signi®cantly more in PrP Sc type-2 than type-1 preparations. Wadsworth et al. (1999) reported that the gel migration characteristics of certain PrP Sc species, hence their conformation, depend on their Cu and Zn ion occupancy. This was based on the observation that chemically chelating for these two metal-ions affected the conformation of PrP Sc , hence their susceptibility toward proteinase K digestion. Although it is not easy to compare our data with those by Wadsworth et al. (1999) because of differences in our classi®cation of human CJD (Parchi et al. 1997) , data from both groups collectively point to variations in metal-ions occupancy as a possible determinant of PrP and phenotypic diversities in prion diseases.
In conclusion, we have shown that major alterations in the distribution and PrP association of metal-ions occur in sCJD; these changes may play a pivotal role in the pathogenesis of prion diseases as they lead to the loss of antioxidant function associated with PrP C and may promote the diversity of PrP Sc and other abnormal PrP species. Whether the metal imbalance is a contributory cause or a mere consequence of PrP C conversion to abnormal isoforms remains to be determined. Finally, this study also presented two potential approaches in the diagnosis of human CJD; the signi®cant increase of Mn in the frontal cortex makes it potentially detectable by clinical magnetic resonance imaging because of its paramagnetic property, and the binding of Mn by PrP in sCJD, but not in the control, might represent a novel diagnostic marker.
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